ABC's The Business: Interview with Dr Jackie Fairley following AstraZeneca deal
Ticky Fullerton of ABC's The Business interview's Starpharma CEO Dr Jackie Fairley following a 20% share price increase "on the back of a deal signed with American drug giant AstraZeneca. It will use Starpharma's drug delivery nanotechnology to target cancer treatment in the body."
The Australian: Starpharma signs AstraZeneca deal
The Australian's Sarah Jane Tasker reports that "Starpharma has inked a potential billiondollar-plus deal with pharmaceutical giant AstraZeneca for the use of its drug delivery technology. AstraZeneca will use Starpharma's technology to develop and commercialise specific cancer drugs, leaving the rest of the oncology space open for Starpharma to further commercialise DEP with third parties".
The Age and SMH: Starpharma shares soar 21 percent on AstraZeneca deal news
Tim Binstead reports on the deal between Starpharma and AstraZeneca that could be worth more than the $US450 million per drug using Starpharma's drug delivery technology, providing "hard proof" that Starpharma's drug delivery platform could be worth billions.
Starpharma signs drug delivery license with AstraZeneca
Starpharma today announced the signing of a licensing agreement with global pharmaceutical company AstraZeneca. The agreement enables the development and commercialisation by AstraZeneca of compounds directed at a defined family of targets using Starpharma’s DEP® drug delivery technology. The DEP® platform centres on use of Starpharma’s proprietary dendrimers, with the aim of enhancing the dosing and efficacy characteristics of pharmaceuticals.
Annual Report and full year financial results
Starpharma today released its annual report and financial results for the year ended 30 June 2015.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2015.
The Australian: Innovative companies 'need a super boost'
The Australian's Sarah-Jane Tasker reports on Starpharma CEO Jackie Fairley's calls for simple changes to superannuation laws similar to those in the US and UK to incentivise individuals and funds to invest in companies like Starpharma and similar technology based companies, which would create a "paradigm shift in investment in the knowledge economy".
She said that "given biotech is a global industry Australia had to ensure there was an environment that encouraged smaller companies to develop into much larger companies and get to a more advanced commercial stage."
AFR and Brisbane Times: Starpharma finds star backers
Tim Binstead reports that Starpharma has found star backers in well-known investment banker Mark Carnegie and property guru James Dack.
Starpharma TV
In the latest episode of Starpharma TV, CEO Dr Jackie Fairley and Jason Lickliter, Principal Investigator and Oncologist, Nucleus Network, Alfred Hospital, Melbourne, discuss Starpharma’s Phase 1 clinical trial of DEP™ docetaxel. They discuss the benefits of the drug compared to docetaxel and the positive initial results from the trial, with the dosage of the drug now exceeding the most commonly used dose for Taxotere® of 75mg/m2, with no dose limiting toxicities, including neutropenia, having been observed to date.
Seeking Alpha - Dendrimers Coming of Age: Starpharma's Star is Rising
DEP (Dendrimer Enhanced Particle) technology improves drug availability, reduces toxicity; potential for repositioning $billion drugs.